![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abteilung Vegetative Physiologie und Pathophysiologie, Georg-August-Universität, Göttingen, Germany
Received February 21, 2005; accepted February 25, 2005
 |
Abstract |
|---|
 Top Abstract References |
|---|
Meanwhile, several families of polyspecific transporters for organic cations and anions exist: the ATP-driven multidrug resistance transporters [e.g., MDR, P-glycoprotein; ABCB1 (Ambudkar et al., 1999
)] and multidrug resistance-associated proteins [MRPs; ABCC family (König et al., 1999; Borst et al., 2000)], as well as the ATP-independent families of organic anion transporting polypeptides [OATPs; solute carrier family SLC21 (Hagenbuch and Meier, 2004)] and organic cation and anion transporters [OCTs, OCTNs, OATs; solute carrier family SLC22 (Koepsell and Endou, 2004)]. The members of the SLC22 family belong to the major facilitator superfamily of uniporters, symporters, and antiporters, which occur in bacteria, lower eukaryotes, plants, and mammals. All members of the SLC22 family are polyspecific and interact with a vast number of endogenous and exogenous compounds including frequently used drugs. In this issue of Molecular Pharmacology, Hermann Koepsell and his associates offer novel insights into the molecular basis of polyspecificity of the rat organic cation transporter 1 (OCT1) (Gorboulev et al., 2005; Popp et al., 2005).
The substrate specificity of the organic cation transporters has been studied in detail previously (Koepsell et al., 2003; Koepsell, 2004). The transporters OCT1 and/or OCT2, for instance, interact not only with endogenous compounds, such as choline, dopamine, histamine, and 5-hydroxytryptamine, but also with receptor antagonists (e.g., phenoxybenzamine, cimetidine), receptor agonists (clonidine, O-methylisoprenaline), ion channel blockers (procainamide, quinidine, mepiperphenidol, verapamil), psychoactive drugs (desipramine), antivirals (acyclovir, ganciclovir), antidiabetic agents (metformin, phenformin), antimalarial agents (quinine), and other drugs (Koepsell, 2004). A detailed comparison between rat OCT1 and rat OCT2 performed earlier (Arndt et al., 2001) laid the basis for the present contribution by Gorboulev et al. (2005) in this issue. Using electrophysiological and tracer techniques, Arndt et al. (2001) found a series of substances for which OCT1 and OCT2 had considerably different affinities. These substances included cyanine 863, quinine, procainamide, mepiperphenidol, and O-methylisoprenaline, which showed 5 to 70 times higher IC50 values (i.e., had lower affinities) for OCT2 than for OCT1, and corticosterone, which, in contrast, inhibited OCT2 at lower concentrations than OCT1 (IC50 of 4 µM versus an IC50 of 151 µM).
Gorboulev et al. (2005) ascertained which regions in the OCT1 and OCT2 proteins might be responsible for the differential affinity toward corticosterone. They fragmented rat OCT2 into 16 pieces containing individual transmembrane helices or intra-/extracellular loops connecting the helices and inserted each of these pieces into rat OCT1. It turned out that the tenth transmembrane domain of OCT2 was responsible for the high affinity for corticosterone. The authors went on to identify which amino acids within the tenth transmembrane helix are contributing to this high affinity and found three: isoleucine 443, tyrosine 447, and glutamate 448. The respective amino acids in OCT1 are alanine 443, leucine 447, and glutamine 448. Replacement of alanine, tyrosine, and glutamate of OCT1 by the respective amino acids of OCT2 increased the affinity of the mutant OCT1 for corticosterone, and, conversely, insertion of the three critical OCT1 amino acids into OCT2 decreased the affinity of the mutant OCT2 for corticosterone. These experiments revealed for the first time components of the binding site for glucocorticoids on OCT1 and OCT2, and, since glucocorticoids interfere with organic cation transport, revealed that transmembrane helix 10 contributes to the organic cation binding site.
In the contribution by Popp et al. (2005), the authors mutated eighteen amino acids in the fourth transmembrane helix of rat OCT1, and tested each mutant for its ability to translocate the organic cations tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP). The replacement of two residues, tryptophan 218 by tyrosine, and tyrosine 222 by leucine, increased the affinity for both TEA and MPP, whereas the threonine 226 to alanine (T226A) mutant had a higher affinity for MPP alone. These "hot spots" were investigated in further detail using additional organic cations for uptake. Other amino acid replacements (e.g., tryptophan 218) had an impact on the selectivity or preference of OCT1 for different cations. It is interesting that tryptophan 218, tyrosine 222, and threonine 226 are located on one side of the fourth transmembrane domain, together with lysine 215 and valine 229. These five amino acids are conserved in all OCTs and therefore are most probably of great functional importance.
Many articles dealing with structure-function relationships of transporters end with the statement that further conclusions necessitate X-ray analysis of crystallized transporters. Popp et al. provide an alternative: they used the previously published structure of the lactose permease of Escherichia coli (Abramson et al., 2003) as a template, and computed the three-dimensional structure of rat OCT1. The calculations revealed a large cleft of about 20 x 60 Å that OCT1 exposes to the cytosolic side of the cell membrane. The above-mentioned three amino acids of the fourth transmembrane helix binding TEA and MPP, the three residues in the tenth transmembrane helix binding corticosterone, and aspartate 475 [identified previously as contributing to organic cation binding (Gorboulev et al., 1999)] are all located in the large cleft and are therefore easily accessible for organic cations. The clusters of functionally important residues turned out to be spatially separated, offering various niches for binding of organic cations. Nonidentical but overlapping binding sites for organic cations have been postulated earlier on the basis of the first mutational studies on OCT1 (Gorboulev et al., 1999) and are strongly supported by the present findings.
Why are the articles by Gorboulev et al. (2005) and Popp et al. (2005) an important development in the field? First, they provide an example of a thorough and analytical characterization of transporters and mutants thereof, using several control experiments, an investigation that took the authors 3 years to complete. Second, the strategy to use differential affinities of two transporters for the detection of amino acids involved in the binding of corticosterone can be adopted to other transporters of the SLC22 family, and possibly to members of other transporter families. Third, we are learning from these two contributions how nature makes transporters polyspecific (e.g., by offering large sites with various anchor points for binding). Subsequent experiments exploiting further substrates will refine the present picture.
|
Footnotes |
|---|
Please see the related articles on pages page 1600 and page 1612.
ABBREVIATIONS: OCT1, organic cation transporter 1; TEA, tetraethylammonium; MPP, 1-methyl-4-phenylpyridinium.
Address correspondence to: Gerhard Burckhardt, Abteilung Vegetative Physiologie und Pathophysiologie, Georg-August-Universität, Humboldtallee 23, 37073 Göttingen, Germany. E-mail: gburckh{at}gwdg.de
|
References |
|---|
|
TopAbstractReferences |
|---|
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398.[CrossRef][Medline]
Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppartz S, Bamberg E, Nagel G, et al. (2001) Interaction of cations, anions and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol 281: F454–F468.
Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295–1302.
Gorboulev V, Shatskaya N, Volk C, and Koepsell H (2005) Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol Pharmacol 67: 1612–1619.
Gorboulev V, Volk C, Arndt P, Akhoundova A, and Koepsell H (1999) Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol Pharmacol 56: 1254–1261.
Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflueg Arch Eur J Physiol 447: 653–665.[CrossRef][Medline]
Koepsell H (2004) Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 25: 375–381.[CrossRef][Medline]
Koepsell H and Endou H (2004) The SLC22 drug transporter family. Pflueg Arch Eur J Physiol 447: 666–676.[CrossRef][Medline]
Koepsell H, Schmitt B, and Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150: 36–90.[Medline]
König J, Nies AT, Cui Y, Leier I, and Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377–394.[Medline]
Popp C, Gorboulev V, Müller TD, Gorbunov D, Shatskaya N, and Koepsell H (2005) Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol 67: 1600–1611.
This article has been cited by other articles:
|
|
 |
|
  M. Slack, C. Kirchhoff, C. Moller, D. Winkler, and R. Netzer Identification of Novel Kv1.3 Blockers Using a Fluorescent Cell-Based Ion Channel Assay J Biomol Screen, February 1, 2006; 11(1): 57 - 64. [Abstract] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
